Table 5.

Multivariate analyses (cox regression) of relapse-free survival and overall survival^a

Variables	Relapse-free survival				Overall survival
		95% CI				95% CI
	HR	Lower	Upper	P	HR	Lower	Upper	P
Whole cohort (n = 86)
Ageb	3.083	0.184	51.762	0.434	3.252	1.322	8.002	0.010*
NPM1c	0.087	0.012	0.604	0.014*	0.392	0.128	1.195	0.100
FLT3-ITDd	21.079	1.427	311.302	0.026*	4.532	1.395	14.723	0.012*
FLT3-TKD	19.630	1.539	250.445	0.022*	1.801	0.184	17.603	0.613
CEBPAe	0.408	0.144	1.154	0.091	0.398	0.147	1.080	0.070
IDH1c	0.448	0.039	5.167	0.520	0.648	0.128	3.268	0.599
IDH2c	0.583	0.025	13.640	0.737	0.254	0.036	1.781	0.168
DNMT3Ac	0.292	0.041	2.098	0.221	0.731	0.158	3.380	0.689
MLLc	31.310	0.729	1344.29	0.073	1.040	0.215	5.020	0.961
MN1	1.391	1.027	1.883	0.033*	1.195	1.025	1.394	0.023*
ERG	5.799	0.548	61.325	0.144	2.545	0.993	6.520	0.052
miR-181a	0.824	0.598	1.135	0.236	0.860	0.692	1.069	0.174
miR-3151	1.183	0.750	1.867	0.469	1.285	0.884	1.866	0.189
BDH2f	2.035	0.472	8.782	0.341	2.547	1.094	6.685	0.050*

Abbreviations: HR indicates Hazard ratio; CI, confidence interval.

^aOnly patients with intensive induction chemotherapy enrolled.

^bAge > 60 relative to Age ≤ 60 (the reference).

^cNPM1^mut versus NPM1^{wild type}; IDH1^mut versus IDH1^{wild type}; IDH2^mut versus IDH2^{wild type}; DNMT3A^mut versus DNMT3A^wild type ; MLL^mut versus MLL^wild.

^dFLT3-ITD^mut versus FLT3-ITD^neg.

^eCEBPA^{double-mutation} versus CEBPA^{single mutation} versus CEBPA^{no mutation}.

^fBDH2^high relative to BDH2^low group.

*Statistically significant (P < 0.05).